

To,

**National Stock Exchange of India Limited**

"Exchange Plaza", 5<sup>th</sup> Floor, Plot No. C-1, Block G,

Bandra - Kurla Complex, Bandra (E),

Mumbai – 400051, Maharashtra, India

**Symbol: MANGALAM**

**Sub.: Submission of report of complaints / comments received by Mangalam Drugs and Organics Limited on the draft Scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("MLPL" or "First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("SJPLL" or "Second Transferor Company") with Mangalam Drugs and Organics Limited ("MDOL" or "Transferee Company" or "Company") and their respective Shareholders.**

**Ref: Our Application Vide No. 40804 filed on 25<sup>th</sup> June, 2024 for obtaining No Objection Certificate from Exchange for proposed Scheme of Merger by Absorption under Regulations 37 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.**

Dear Sir / Madam,

This is with reference to the draft Scheme of Merger by Absorption of Mangalam Laboratories Private Limited ("MLPL" or "First Transferor Company") and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) ("SJPLL" or "Second Transferor Company") with Mangalam Drugs and Organics Limited ("MDOL" or "Transferee Company" or "Company") and their respective Shareholders ("Scheme"), submitted to you vide our Application No 40804 on June 25, 2024.

In compliance with the requirements of paragraph 6 of SEBI Master Circular no. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, (SEBI Master Circular), we submit herewith the "Report on Complaints", in the format prescribed at Annexure IV of said Circular.

As set out in the annexed 'Report on Complaints', we wish to confirm that MDOL has not received any complaints / comments in respect of the Scheme up to July 17, 2024 either directly or through the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) ("NSE" and "BSE" hereafter collectively referred to as "Stock Exchanges") and Securities & Exchange Board of India (SEBI).

# Mangalam Drugs and Organics Limited

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413



In accordance with paragraph 6 (b) said Circular, the 'Report on Complaints' shall also be uploaded on our website at the following link <https://www.mangalamdrugs.com/scheme-of-merger/>.

We request you to kindly take the above on record.

Yours faithfully,

**For and on behalf of  
Mangalam Drugs and Organics Limited**

**Govardhan M. Dhoot**

**Managing Director**

**DIN : 01240086**

**Date : 20.07.2024**

**Place : Mumbai**

## Report on Complaints

### Part A

Sr. No.	Particulars	Number
1.	Number of complaints received directly	Nil
2.	Number of complaints forwarded by Stock Exchanges	Nil
3.	Number of complaints forwarded by SEBI	Nil
4.	Total Number of complaints / comments received (1+2+3)	Nil
5.	Number of complaints resolved	Not Applicable
6.	Number of complaints pending	Not Applicable

### Part B

Name of Complainant	Date of Complaint	Status (Resolved / Pending)
Not Applicable		

For and on behalf of  
Mangalam Drugs and Organics Limited

**Govardhan M. Dhoot**

**Managing Director**

**DIN** : 01240086

**Date** : 20.07.2024

**Place** : Mumbai